Semaglutide

WHAT IT IS

Semaglutide is a synthetic peptide medication that mimics glucagon-like peptide-1 (GLP-1), a hormone released by the gut in response to food. Because it activates the GLP-1 receptor, it is described as a GLP-1 receptor agonist.

It is FDA-approved in the United States under separate brand names for two distinct purposes: management of type 2 diabetes, and chronic weight management in adults who meet specific clinical criteria. An oral tablet form is also approved for type 2 diabetes. FDA status: Approved for type 2 diabetes and chronic weight management (as Ozempic and Wegovy, plus Rybelsus tablets for type 2 diabetes); other uses are investigational.

Semaglutide is a prescription medication. It is not a supplement, and it is not something to source outside of a licensed clinician and a regulated pharmacy.

ESTABLISHED USE AND RESEARCH HISTORY

Semaglutide has been studied across a large, multi-year clinical trial program including:

• Blood sugar control in type 2 diabetes (the SUSTAIN program)
• Chronic weight management in adults with obesity or overweight with weight-related conditions (the STEP program)
• Cardiovascular outcomes in people with type 2 diabetes and in people with obesity and established cardiovascular disease
• Kidney outcomes in people with type 2 diabetes and chronic kidney disease
• Ongoing research in related metabolic and inflammatory conditions

This is a genuinely deep evidence base. It includes tens of thousands of participants, multi-year follow-up, and hard clinical endpoints rather than short-term surrogate markers alone.

HOW IT WORKS / MECHANISM

GLP-1 is released after eating and acts on receptors in the pancreas, the gut and the brain. Semaglutide is designed to activate those same receptors, but with a much longer duration of action than the natural hormone.

• Appetite and satiety: GLP-1 signaling in the brain increases the sense of fullness and reduces the drive to eat, including the persistent food-related thoughts many people describe as food noise.
• Gastric emptying: food leaves the stomach more slowly, which prolongs fullness after a meal and also explains much of the nausea people report.
• Insulin secretion: insulin release is enhanced in a glucose-dependent way, meaning it acts mainly when blood sugar is elevated.
• Glucagon signaling: inappropriate glucagon release after meals is reduced, which lowers glucose output from the liver.
• Overall calorie intake: the practical result of the above is that most people spontaneously eat less without deliberately restricting.

It is worth being clear about what that last point means. Semaglutide does not remove calories from food. It changes appetite signaling, and the weight change follows from eating less over time.

HOW IT COMPARES WITH TIRZEPATIDE AND RETATRUTIDE

These three compounds are most easily understood by how many hormone receptors they act on.

• Semaglutide primarily targets one receptor: GLP-1. It is FDA-approved.
• Tirzepatide targets two receptors: GIP and GLP-1. It is FDA-approved.
• Retatrutide targets three receptors: GIP, GLP-1 and glucagon. It remains investigational and is not FDA-approved.

Additional receptor targets do not automatically make a therapy better, safer or more appropriate for any individual person. Tolerability, medical history, other medications, cost, insurance coverage, approval status and the goal of treatment all matter, and for many people the medication with the longest track record is the more sensible starting conversation.

The right comparison is made with a physician who knows your full clinical picture, not by counting receptors.

WHAT THE EVIDENCE ACTUALLY SHOWS

In type 2 diabetes trials, semaglutide produced clinically meaningful reductions in HbA1c alongside weight reduction, and cardiovascular outcome research reported reduced risk of major adverse cardiovascular events in studied populations.

In chronic weight management trials, average weight reduction was substantially greater than placebo and sustained over the treatment period, with results varying considerably between individuals.

Research also consistently shows that weight tends to return after the medication is stopped unless eating patterns, training and other habits have genuinely changed. This is one of the most important and most frequently ignored findings in the entire dataset.

SAFETY AND PRACTICAL CONSIDERATIONS

• Gastrointestinal effects such as nausea, vomiting, diarrhea and constipation are the most commonly reported side effects.
• Labeling includes a boxed warning regarding thyroid C-cell tumors observed in rodents, and the medication is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
• Pancreatitis, gallbladder disease, dehydration-related kidney injury and, in some people, worsening of diabetic retinopathy have been reported and are described in prescribing information.
• Interactions with other glucose-lowering medications, particularly insulin and sulfonylureas, require clinical management.
• Appetite reduction can make it easy to under-eat protein and total nutrition, which has direct consequences for muscle and bone.

These considerations are best addressed through medical supervision rather than self-directed use.

FDA-APPROVED VERSUS COMPOUNDED AND RESEARCH-MARKET PRODUCTS

FDA-approved semaglutide products are manufactured under regulated conditions, carry approved prescribing information, and have verified identity, purity, sterility and labeling.

Compounded semaglutide is a different category. Compounded products are not FDA-approved and are not reviewed for safety, effectiveness or quality in the same way. Regulators have documented dosing errors, adverse events and products containing salt forms of semaglutide that are not the approved active ingredient.

Products sold online as research chemicals, research peptides or not for human use sit entirely outside the regulated supply chain. Identity, dose accuracy and sterility cannot be assumed at all.

The safety record people cite when they talk about semaglutide was generated with the approved medication. It does not transfer to an unverified vial.

PROTECTING LEAN MASS DURING WEIGHT LOSS

Any substantial weight loss, from any method, includes some loss of lean tissue along with fat. For adults over 40 this is the part of the conversation that matters most, because muscle and bone are what protect strength, metabolic health, balance and independence later in life.

• Resistance training two to four times per week, covering the major movement patterns, is the strongest available signal to preserve muscle during a calorie deficit.
• Adequate protein at every meal, spread through the day rather than concentrated at dinner, supports muscle retention even when total intake falls.
• Enough total nutrition to support training, including sufficient fiber, fluid and micronutrients, particularly when appetite is suppressed.
• Daily walking and general movement to maintain overall activity as appetite and energy intake decline.
• Reasonable rate of loss and adequate sleep, both of which influence how much of the loss comes from fat versus muscle.

A medication can change appetite. It cannot lift weights for you, and it cannot make protein appear on your plate.